Bristol Aims To Be First To Market With Novel Diabetes Drug Class
Bristol and AstraZeneca ink deal potentially worth over $1 billion to develop Bristol’s prospective first-in-class SGLT-2 inhibitor and DPP-4 candidate saxagliptin.
Bristol and AstraZeneca ink deal potentially worth over $1 billion to develop Bristol’s prospective first-in-class SGLT-2 inhibitor and DPP-4 candidate saxagliptin.